Pancreatic and Bile Duct Stone Management Market

Pancreatic and Bile Duct Stone Management Market Outlook (2024 to 2034)

Fact.MR, a market research and intelligence provider, places the revenue in the global pancreatic and bile duct stone management market size at US$ 1.36 billion in 2024. The market is projected to expand at a CAGR of 4.5% to arrive at US$ 2.12 billion by the end of 2034.

Bile duct and pancreatic stones are also referred to as gallstones. These are tiny, pebble-like formations made of the gallbladder's or the pancreas' hardened fluids. While gallstones that are still in the gallbladder are not harmful, a biliary stone is created when a gallstone travels to the bile duct and becomes lodged there.

Bile can develop anywhere in the biliary tract, including the liver, gallbladder, and common bile duct, leading to infection and other significant issues. Usually composed of calcium carbonate fragments that have solidified as a result of digestive enzymes, pancreatic stones are lodged in the duct that connects the pancreas to the small intestine.

Key Market Growth Drivers

• Rising prevalence of common bile duct and pancreatic stone diseases is boosting demand for stone retrieval procedures and minimally invasive stone extraction procedures.
• Pancreatic and bile duct stone management market growth is influenced by the technological advancements in equipment for managing pancreatic and bile duct stones as well as an increase in the introduction of extremely advanced endoscopic medical devices.
• Rising healthcare costs and increasing awareness of the importance of early diagnosis are other factors responsible for the adoption of pancreatic and stone management procedures.
• There is a growing emphasis on clinical efficacy and increased funding for the development of innovative products for managing bile duct and pancreatic stones.
• Open surgery was previously available, endoscopic retrograde cholangiopancreatography (ERCP) and laparoscopic cholecystectomy (LC) have almost completely replaced laparotomy due to their well-known benefits.
• Use of ERCP as a first-line treatment for managing common and pancreatic bile duct stones is increasing as a result of these advantages.
• Since ERCP, sphincterotomy, stents, and lithotripsy have been associated with a higher risk of pancreatitis and other complications, the introduction of alternative treatments for these conditions is benefitting market players.

Report Attribute	Detail
Pancreatic and Bile Duct Stone Management Market Size (2024E)	US$ 1.36 Billion
Forecasted Market Value (2034F)	US$ 2.12 Billion
Global Market Growth Rate (2024 to 2034)	4.5% CAGR
East Asia Market Share (2024E)	6.9%
North America Market Share (2024E)	52.5%
Sphincterotomes Segment Value (2024E)	US$ 273.2 Million
Key Companies Profiled	Conmed Endoscopic Technologies; Boston Scientific Corporation; CR BARD Inc. (Becton, Dickinson and Company); Cordis (Cardinal Health Inc.); Zeon Medical Co., Ltd.; Medi-Globe (ENDO-Flex) GmbH; Taewoong Medical Co. Ltd.; Q3 Medical Device; Medtronic Inc.

What is Contributing to Increasing Need for Pancreatic and Bile Duct Stone Management?

“Focus on Clinical Effectiveness and Investments in Innovative Product Development”

Technological innovations in products designed for the management of pancreatic and bile duct stones, alongside the proliferation of highly sophisticated endoscopic medical devices, are contributing to the expansion of the pancreatic and bile duct stone management market size. In addition, escalating healthcare expenses, early detection, and heightened awareness contribute to market growth. Moreover, the growing emphasis on clinical effectiveness and increased investments in the development of innovative products for treating bile duct and pancreatic stones are contributing to revenue streams.

• As outlined in the guidelines issued by the European Society of Gastrointestinal Endoscopy (ESGE), ERCP procedures are recommended for the treatment of 80% to 90% of pancreatic and bile duct stones.

How is Complexity of ERCP Procedures Affecting Market Expansion?

“Intricate Nature of ERCP Procedures Leading to Safety Concerns and Decreased Adoption”

ERCP is a complex endoscopic procedure that requires extensive experience and training to be performed effectively and safely. The lack of uniform regulations allowing qualified endoscopists to perform ERCP is expected to lead to a rise in ERCP complications, which is projected to ultimately hinder market expansion. With a mortality and morbidity rate of 5–10% and 0.1–1%, respectively, it is the riskiest procedure that gastrointestinal endoscopists regularly perform.

Country-wise Insights

North America is estimated to account for 52.5% of the global pancreatic and bile duct stone management market share in 2024. Increasing prevalence of gastrointestinal conditions in India is expected to create significant growth opportunities for minimally invasive techniques. The low cost of devices such as metal stents and self-expanding balloons for managing stones in the bile duct is also driving market growth.

Will Favorable Reimbursement Scenario Influence Market Growth in the United States?

“Increases Capacity of Market Players to Invest in Research, Development, and Innovation”

Attribute	United States
Market Value (2024E)	US$ 655 Million
Growth Rate (2024 to 2034)	4.2% CAGR
Projected Value (2034F)	US$ 984 Million

The United States is poised to hold a market share of 91.4% in 2024 in North America. The yearly incidence of stones in the United States has been steadily increasing, and this trend is expected to hold for the next 10 years. The country is a lucrative market for treatment providers due to its enormous potential for healthcare spending.

• Gallstones affect 14.2 million men and over 6.3 million women between the ages of 20 and 74 in the United States, according to Statpearls. Although 10% of patients experience symptoms within five years of diagnosis, and 20% of patients will experience symptoms within 20 years, the majority of gallstone patients do not exhibit any symptoms.

Favorable government programs and reimbursement scenarios are also improving the capacity of different players in the market to produce innovative medications. This is a key pancreatic and bile duct stone management market trend in the United States.

How is the Market Faring in South Korea?

“Rising Awareness Leading to Early Detection and Diagnosis of Pancreatic and Bile Duct Stones”

Attribute	South Korea
Market Value (2024E)	US$ 36 Million
Growth Rate (2024 to 2034)	5.1% CAGR
Projected Value (2034F)	US$ 60 Million

Rise of the pancreatic and bile stone management market in South Korea is due to increasing awareness about pancreatic and bile duct disorders among both healthcare professionals and the general population. This has led to early detection and diagnosis of these conditions, resulting in growing demand for management and treatment options.

Advancements in medical technology and healthcare infrastructure in South Korea have contributed to the growth of the market. The availability of state-of-the-art medical facilities and skilled healthcare professionals has made the country a preferred destination for patients seeking treatment for pancreatic and bile duct disorders. The growing elderly population in South Korea has led to an increased prevalence of pancreatic and bile duct disorders, further driving the demand for management solutions.

Category-wise Insights

The global pancreatic and bile duct stone management market is categorized into ERCP catheters, biliary stents, guidewires, sphincterotomes, dilation balloon catheters, self-expandable biliary stents, and lithotripsy based on product type. Sphincterotomes are estimated to hold 20% of the market in 2024. In terms of end user, ambulatory surgical centers and specialty clinics collectively account for 55% market share in 2024.

Which Product is Effective in Pancreatic and Bile Duct Stone Management?

“Enhanced Safety and Fewer Adverse Effects Associated with Sphincterotomes”

Attribute	Sphincterotome
Segment Value (2024E)	US$ 273.2 Million
Growth Rate (2024 to 2034)	4.4% CAGR
Projected Value (2034F)	US$ 421 Million

Because of increased demand and reduced side effects, the sphincterotome product within the pancreatic and bile duct stone management segment is anticipated to experience growth in the forecast period, surpassing ERCP catheters in popularity. Patients are transitioning from ERCP catheters to sphincterotome treatment due to its enhanced safety, minimal side effects, and superior therapeutic effectiveness. The segment’s expansion is additionally fueled by technological approvals for lithotripsy and a noteworthy success rate in sphincterotome procedures along with associated treatments.

Which Indication Accounts for High Revenue Generation?

“Increasing Number of Procedures to Treat Pancreatic Stones Caused by Chronic Illnesses”

Attribute	Pancreatic Stones
Segment Value (2024E)	US$ 321 Million
Growth Rate (2024 to 2034)	5.2% CAGR
Projected Value (2034F)	US$ 529.2 Million

Growth of the pancreatic stones segment is set to be driven by the rising number of chronic illnesses brought on by pancreatic stone formation. Globally, there is a growing need for pancreatic stone protein testing due to the prevalence of conditions such as acute appendicitis, diabetes, and optic atrophy.

The market for pancreatic stones is driven by changes in lifestyle, such as increased alcohol consumption, which causes acute pancreatitis. Despite substantial research, biomarkers such as pancreatic stone protein testing with high sensitivity and specificity are still lacking, and the symptoms of acute pancreatitis are nonspecific.

Competition Analysis

Key players in the pancreatic and bile duct stone management market are expected to introduce new technologies for hepatocellular and biliary stents.

• Boston Scientific Corporation stated in December 2022 that it would make a partial offer, up to a maximum of 65% of the company's shares, to acquire a majority stake in Acotec, a Chinese medical technology company that manufactures products for a range of interventional procedures.
• In December 2022, Calci Medica, Inc. conducted a Phase II clinical dose-ranging trial for Auxora in patients suffering from acute pancreatitis and systemic inflammatory response syndrome.
• In March 2022, AcelRx Pharmaceuticals, Inc. published findings from a comparison of two distinct dialysis circuit anticoagulants, citrate anticoagulation (RCA) and napamostat, in pediatric patients receiving continuous renal replacement therapy (CRRT).

Fact.MR provides detailed information about the price points of prominent players in the pancreatic and bile duct stone management market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Pancreatic and Bile Duct Stone Management Market Research

• By Product :

  • ERCP Catheters
  • Guidewires
  • Sphincterotomes
  • Dilation Balloon Catheters
  • Extraction Balloon Catheters
  • Extraction Basket Catheters
  • Biliary Stents
  • Self-Expandable Biliary Stents
  • Dilation Large-Balloon Catheters
  • Mechanical Lithotripsy
  • Electrohydraulic/Laser Lithotripsy

• By Indication :

  • Pancreatic Stones
  • Bile Duct Stones

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa